This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sutphen, R. Articles by Krischer, J. P. Search for Related Content PubMed PubMed Citation Articles by Sutphen, R. Articles by Krischer, J. P.

Lysophospholipids Are Potential Biomarkers of Ovarian Cancer

Departments of ¹ Interdisciplinary Oncology, ² Obstetrics and Gynecology, and ³ Gynecologic Oncology, College of Medicine and H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida; ⁴ Cleveland Clinic Foundation, Cleveland, Ohio; ⁵ Department of Gynecologic Oncology, Bayfront Medical Center, St. Petersburg, Florida; ⁶ Morton Plant Hospital, Clearwater, Florida; ⁷ New England Medical Center, Tufts University, Boston, Massachusetts; and ⁸ Bay Area Oncology, Tampa, Florida

Requests for reprints: Rebecca Sutphen, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Drive, FOW-LCS, Tampa, FL 33612. Phone: 813-903-4990; Fax: 813-558-4807. E-mail: rsutphen{at}hsc.usf.edu

Objective: To determine whether lysophosphatidic acid (LPA) and other lysophospholipids (LPL) are useful markers for diagnosis and/or prognosis of ovarian cancer in a controlled setting. Method: Plasma samples were collected from ovarian cancer patients and healthy control women in Hillsborough and Pinellas counties, Florida, and processed at the University of South Florida H. Lee Moffitt Cancer Center and Research Institute (Moffitt). Case patients with epithelial ovarian cancer (n = 117) and healthy control subjects (n = 27) participated in the study. Blinded LPL analysis, including 23 individual LPL species, was performed at the Cleveland Clinic Foundation using an electrospray ionization mass spectrometry–based method. LPL levels were transmitted to Moffitt, where clinical data were reviewed and statistical analyses were performed. Results: There were statistically significant differences between preoperative case samples (n = 45) and control samples (n = 27) in the mean levels of total LPA, total lysophosphatidylinositol (LPI), sphingosine-1-phosphate (S1P), and individual LPA species as well as the combination of several LPL species. The combination of 16:0-LPA and 20:4-LPA yielded the best discrimination between preoperative case samples and control samples, with 93.1% correct classification, 91.1% sensitivity, and 96.3% specificity. In 22 cases with both preoperative and postoperative samples, the postoperative levels of several LPL, including S1P, total LPA, and lysophosphatidylcholine (LPC) levels and some individual species of LPA and LPC, were significantly different from preoperative levels. Conclusion: LPA, LPI, LPC, and S1P appear useful as diagnostic and prognostic biomarkers of ovarian cancer.

This article has been cited by other articles:

				Z. Zhao, Y. Xiao, P. Elson, H. Tan, S. J. Plummer, M. Berk, P. P. Aung, I. C. Lavery, J. P. Achkar, L. Li, et al. Plasma Lysophosphatidylcholine Levels: Potential Biomarkers for Colorectal Cancer J. Clin. Oncol., July 1, 2007; 25(19): 2696 - 2701. [Abstract] [Full Text] [PDF]

				T.-V. Do, J. C. Symowicz, D. M. Berman, L. A. Liotta, E. F. Petricoin III, M. S. Stack, and D. A. Fishman Lysophosphatidic Acid Down-Regulates Stress Fibers and Up-Regulates Pro-Matrix Metalloproteinase-2 Activation in Ovarian Cancer Cells Mol. Cancer Res., February 1, 2007; 5(2): 121 - 131. [Abstract] [Full Text] [PDF]

				F.-q. Wang, Y. Smicun, N. Calluzzo, and D. A. Fishman Inhibition of Matrilysin Expression by Antisense or RNA Interference Decreases Lysophosphatidic Acid-Induced Epithelial Ovarian Cancer Invasion Mol. Cancer Res., November 1, 2006; 4(11): 831 - 841. [Abstract] [Full Text] [PDF]

				J. Ren, Y.-j. Xiao, L. S. Singh, X. Zhao, Z. Zhao, L. Feng, T. M. Rose, G. D. Prestwich, and Y. Xu Lysophosphatidic Acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res., March 15, 2006; 66(6): 3006 - 3014. [Abstract] [Full Text] [PDF]

				B. W. Parks, G. P. Gambill, A. J. Lusis, and J. H. S. Kabarowski Loss of G2A promotes macrophage accumulation in atherosclerotic lesions of low density lipoprotein receptor-deficient mice J. Lipid Res., July 1, 2005; 46(7): 1405 - 1415. [Abstract] [Full Text] [PDF]

				J. Symowicz, B. P. Adley, M. M.M. Woo, N. Auersperg, L. G. Hudson, and M. S. Stack Cyclooxygenase-2 Functions as a Downstream Mediator of Lysophosphatidic Acid to Promote Aggressive Behavior in Ovarian Carcinoma Cells Cancer Res., March 15, 2005; 65(6): 2234 - 2242. [Abstract] [Full Text] [PDF]